POS1011 PREDICTORS OF ENDOTHELIAL DYSFUNCTION IN ANKYLOSING SPONDYLITIS

Background: Cardiovascular (CV) disease is the leading cause of death in Ankylosing Spondylitis (AS). Chronic systemic inflammation driven endothelial dysfunction to accelerated atherosclerosis results premature mortality. Endothelial potentially treatable hence a therapeutic target. Predictive biomarkers for would allow tailoring therapy individual. Objectives: To assess AS context markers and oxidative stress patients. Methods: Sub group–analysis our previous studies 1-3 was carried out 80 patients were compared with 40 healthy controls matched age sex that also part these studies. 2,3 Such analysis had so far not been performed this cohort. Patients traditional CV risk factors excluded Flow-mediated dilatation (FMD), as measure function, assessed by AngioDefender (Everist Health, Ann Arbor, MI). Inflammatory measures included: Bath Disease Activity Index (BASDAI) Score (ASDAS) AS. We assayed inflammation, including C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), proinflammatory cytokines (interleukin [IL]-1, IL-6, tumor necrosis factor [TNF]-α), dysfunction, lipids nitrite marker stress, TBARS. Results: FMD significantly lower [(5.80±0.35% vs. 9.09±0.35%, p≤0.05) reduced approximately 36%] whereas serum nitrite, TBARS, total cholesterol LDL levels higher (p≤0.05). Compared controls, high BASDAI, ASDAS increased concentrations ESR, CRP, TNF-α, IL-6. In AS, inversely correlated ASDAS, CRP (Figure 1A), TNF-α 1B), 1C) TBARS 1) positively HDL Figure 1. Correlation Nitrite Conclusion: impaired, indicating dysfunction. independent predictors AS-related inflammatory mechanisms (TNF-α, IL-6) vascular function (CRP, TBARS) may all be involved development cardiovascular could serve novel targets preventing References: [1]Garg N, Krishan P, Syngle A. Rosuvastatin improves ankylosing spondylitis. Clin Rheumatol. 2015;34:1065-1071. [2]Verma I, A, Garg N. Progenitor Cells Marker Dysfunction Atherosclerosis Spondylitis. International Journal Angiology. 2017;26:36–42. [3]Verma Predictors Rheumatol Ther. 2015;2(2): 173–182. Disclosure Interests: None declared.